CARBIDOPA; LEVODOPA
Clinical safety rating: safe
Nonselective MAOIs are contraindicated and pyridoxine can reverse its effects in the periphery Can cause orthostatic hypotension and hallucinations.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability in the CNS and reducing peripheral side effects.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase and catechol-O-methyltransferase (COMT) in peripheral tissues. Carbidopa is metabolized to a lesser extent, with both drugs undergoing hepatic metabolism. |
| Excretion | Levodopa: primarily renal (70-80% as metabolites, including dopamine and homovanillic acid); carbidopa: renal (30% unchanged, remainder as metabolites). Fecal excretion is minimal (<5%). |
| Half-life | Levodopa: 1-3 hours (short, requires frequent dosing); carbidopa: 1-2 hours. Clinically, the combination extends half-life but does not significantly alter terminal elimination. |
| Protein binding | Levodopa: ~10-30% (primarily to albumin); carbidopa: ~30% (albumin). |
| Volume of Distribution | Levodopa: 0.9-1.6 L/kg (extensively distributed, but poor CNS penetration due to peripheral metabolism); carbidopa: 0.5-1 L/kg. |
| Bioavailability | Oral (levodopa): ~30% (when administered with carbidopa, carbidopa inhibits peripheral decarboxylation, increasing levodopa bioavailability to ~99% of the absorbed dose). Carbidopa: oral bioavailability ~40-70%. |
| Onset of Action | Oral: 0.5-2 hours (first noticeable improvement in parkinsonian symptoms). |
| Duration of Action | Oral: 4-6 hours (with standard immediate-release formulation). Clinical duration may be shorter with advanced disease (wearing-off). |
Initial: carbidopa 25 mg/levodopa 100 mg (1 tablet) orally three times daily; titrate based on response. Maintenance: usually 1 tablet (25/100) three to four times daily, up to 8 tablets/day. Immediate-release, extended-release, and oral disintegrating forms available.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment required for mild-to-moderate renal impairment. For severe renal impairment (eGFR <15 mL/min/1.73 m²), clinical trials lacked data; use with caution. Not removed by hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50% and monitor. Child-Pugh C: contraindicated due to risk of levodopa accumulation and worsening hepatic encephalopathy. |
| Pediatric use | For Parkinson disease (rare; doses based on limited data): initial carbidopa/levodopa 0.5 mg/kg/dose of levodopa component orally three times daily; titrate slowly to maximum 1 mg/kg/dose (levodopa) three times daily for children <30 kg; older children follow adult dosing. For restless legs syndrome (off-label): 1 mg/kg/dose (levodopa) at bedtime. |
| Geriatric use | Initiate with lowest possible dose (e.g., carbidopa 25 mg/levodopa 100 mg twice daily) due to increased sensitivity and risk of adverse effects (hallucinations, dyskinesias, orthostatic hypotension). Titrate slowly over weeks. Monitor for cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Nonselective MAOIs are contraindicated and pyridoxine can reverse its effects in the periphery Can cause orthostatic hypotension and hallucinations.
| FDA category | Animal |
| Breastfeeding | Levodopa is excreted into breast milk in low concentrations; milk-to-plasma ratio (M/P) is approximately 0.2–0.4. Carbidopa excretion is minimal. Breastfeeding is generally considered acceptable, but monitor infant for potential adverse effects such as drowsiness or poor feeding. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Nausea |
| Serious Effects |
["Concurrent use with non-selective MAO inhibitors (within 14 days)","Known hypersensitivity to any component","Narrow-angle glaucoma (relative contraindication)","Suspicious undiagnosed skin lesions or history of melanoma (relative)"]
| Precautions | ["May cause or exacerbate dyskinesias","Risk of neuroleptic malignant syndrome-like syndrome (including hyperpyrexia and confusion) upon rapid dose reduction or withdrawal","May cause hallucinations, psychosis, or depression","May increase risk of melanoma","Cautions in patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic, or endocrine disease","Avoid concomitant use with non-selective MAO inhibitors"] |
| Food/Dietary |
Loading safety data…
| Animal studies have shown fetal abnormalities; first trimester exposure may be associated with a small increased risk of congenital malformations, particularly neural tube defects. Second and third trimester use may be associated with fetal growth restriction and premature labor. Data in humans are limited but suggest potential risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of dyskinesia or mood changes. Fetal monitoring includes ultrasound for growth restriction and anomaly screening. Assess for premature labor symptoms. |
| Fertility Effects | Levodopa/carbidopa may improve infertility related to hyperprolactinemia in Parkinson's disease by reducing prolactin levels. No direct adverse effects on fertility reported; however, data are limited. |
| Avoid high-protein meals because dietary proteins compete with levodopa for absorption, reducing efficacy. Consistent, low-protein meals are recommended. Also avoid iron supplements and multivitamins containing iron as they can chelate levodopa and decrease bioavailability. |
| Clinical Pearls | Carbidopa prevents peripheral decarboxylation of levodopa, increasing CNS availability and reducing peripheral side effects. Administer with meals to decrease GI upset but avoid high-protein meals as they may reduce absorption. Start with a low dose and titrate slowly; abrupt discontinuation may precipitate neuroleptic malignant syndrome. Use with caution in patients with narrow-angle glaucoma, melanoma, or history of psychosis. |
| Patient Advice | Take this medication exactly as prescribed; do not suddenly stop or change dose without consulting your doctor. · It may take several weeks to feel the full benefit; report any unusual movements, confusion, or hallucinations. · Avoid high-protein meals when taking this drug; consistency in meal timing helps maintain steady drug levels. · You may notice a darkening of urine, sweat, or saliva; this is harmless. · Avoid driving until you know how this medication affects you, as dizziness or drowsiness may occur. · Do not take over-the-counter iron supplements or multivitamins containing iron, as they can reduce absorption. |